Use of a Schizosaccharomyces pombe PKA-repressible reporter to study cGMP metabolising phosphodiesterases.
The Schizosaccharomyces pombe fbp1 gene is transcriptionally repressed by protein kinase A (PKA) that is activated by extracellular glucose via a cAMP-signaling pathway. We previously used an fbp1-ura4 reporter that places uracil biosynthesis under the control of the glucose-sensing pathway to identify mutations in genes of the cAMP pathway. More recently, this reporter has been used in high throughput screens for small molecule inhibitors of heterologously-expressed cyclic nucleotide phosphodiesterases (PDEs) that hydrolyse cAMP to 5' AMP. Here we show that strains lacking the adenylyl cyclase gene respond to either exogenous cAMP or cGMP to activate PKA, thus regulating fbp1-ura4 expression and other PKA-regulated processes such as conjugation and the nuclear export of an Rst2-GFP fusion protein. Expression of cGMP-specific PDEs or ones that hydrolyse both cAMP and cGMP increases the amount of exogenous cGMP required to activate PKA in order to repress fbp1-ura4 expression, creating conditions that allow detection of inhibitors of these PDEs. As proof of this concept, we screened a collection of compounds previously identified as inhibitors of cAMP-specific PDE4 or PDE7 enzymes for their ability to inhibit the mammalian cGMP-specific PDE5A enzyme. We identified compound BC76, which inhibits PDE5A in an in vitro enzyme assay with an IC(50) of 232nM. Further yeast-based assays show that BC76 inhibits PDE1, PDE4, PDE5, PDE8, PDE10 and PDE11, thus demonstrating the utility of this system for detecting and characterising inhibitors of either cAMP- or cGMP-metabolising PDEs.
Biology Department, Boston College, 140 Commonwealth Ave., Chestnut Hill, MA 02467, USA. demirbas@bc.edu
Didem
D
Demirbas
Ozge
O
Ceyhan
Arlene R
AR
Wyman
F Douglas
FD
Ivey
Christina
C
Allain
Lili
L
Wang
Maia N
MN
Sharuk
Sharron H
SH
Francis
Charles S
CS
Hoffman
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D002417:Cattle; D017868:Cyclic AMP-Dependent Protein Kinases / Q000235:genetics*; D006152:Cyclic GMP / Q000378:metabolism*; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000096:biosynthesis*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D017930:Genes, Reporter; D006801:Humans; D051379:Mice; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000096:biosynthesis*; D012568:Schizosaccharomyces / Q000235:genetics*
C557321:BC76 compound; D001562:Benzimidazoles; D058986:Phosphodiesterase 5 Inhibitors; D011758:Pyrroles; D011994:Recombinant Proteins; D017868:Cyclic AMP-Dependent Protein Kinases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006152:Cyclic GMP